BOSTON, MAŚRetinopathy of prematurity (ROP) is the second most common cause of childhood blindness in the United States, occurring in half of premature infants born earlier than or at 28 weeks gestational age. The condition is caused by abnormal blood vessel development in the retina of the eye. ROP risk increases with decreasing gestational age.
A study by researchers at Brigham and Women's Hospital (BWH) suggests that the antioxidant, rhSOD (recombinant human Cu/Zn superoxide dismutase), reduces the risk of developing ROP in extremely low gestational age newborns.
The post-hoc analysis study will be published online on June 15, 2012 in Neonatology.
Researchers looked at a subset of data from a previous multicenter trial that randomized 302 preterm infants to receive either rhSOD or placebo for prevention of bronchopulmonary dysplasia (a chronic lung condition that affects newborn babies). Researchers analyzed the data looking specifically at the incidence and severity of ROP in extremely low gestational age newborns.
Within the entire cohort, there were no significant differences in ROP in newborns given placebo versus those given rhSOD. However, those born earlier than 26 weeks (72 babies) had a 22 percent reduction in ROP. The abnormality was reduced by 53 percent for babies born earlier than 25 weeks (24 babies).
"Even though strides have been made in developing interventions to stop ROP from progressing to blindness, there are currently no therapies available for ROP prevention," said Richard Parad, MD, BWH Department of Newborn Medicine, lead study author. "There is a large need for the preventive approach that rhSOD could potentially provide."
The researchers note that while looking at ROP was not the primary outcome for which the prior study was designed, this post-hoc analysis was carefully re-focused on the tiniest babies with the highest ROP risk based on recent advances in the understanding of how ROP develops and on evidence from prior studies of other antioxidants that suggested such agents might interfere with development of ROP.
In light of the findings, the researchers stress that further studies are required to confirm their observations.
This research was supported by Biotechnology General Corporation (now Savient Pharmaceuticals). rhSOD is currently owned by Ferring Pharmaceuticals.
Brigham and Women's Hospital (BWH) is a 793-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare, an integrated health care delivery network. BWH is the home of the Carl J. and Ruth Shapiro Cardiovascular Center, the most advanced center of its kind. BWH is committed to excellence in patient care with expertise in virtually every specialty of medicine and surgery. The BWH medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in quality improvement and patient safety initiatives and its dedication to educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Biomedical Research Institute (BRI), www.brighamandwomens.org/research, BWH is an international leader in basic, clinical and translational research on human diseases, involving more than 900 physician-investigators and renowned biomedical scientists and faculty supported by more than $537 M in funding. BWH is also home to major landmark epidemiologic population studies, including the Nurses' and Physicians' Health Studies and the Women's Health Initiative. For more information about BWH, please visit www.brighamandwomens.org.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.